Science is complicated, and so are the rules that govern how it’s paid for by the federal government. An abrupt Friday afternoon announcement from the
I’ve spent more than two decades of work in biomedical research policy, and there is no issue I hate talking about more than indirect costs.
The National Institutes of Health has made a landmark decision that could irreparably damage the backbone of American scientific innovation: a dramatic reduction in the
Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
In the souring US-China relationship, there are winners and losers. DNA sequencing giant Illumina is both. Illumina got bad news this week when China …
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The Trump administration’s reported plans to potentially lay off thousands of FDA employees could slow the agency’s reviews of new drugs, experts say, in addition
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS